2.5mg Semaglutide: the Starting Dose Explained

The myth worth clearing up first: 2.5mg is not an ineffective dose

A question our prescribers hear most weeks is some version of: "I've read the 2.5mg pen does nothing, should I skip straight to 0.5mg or higher?" The confusion is understandable; the starter dose is often described in shorthand as a "placeholder". That framing misleads.

The 2.5mg step exists by design. Semaglutide slows gastric emptying and acts on GLP-1 receptors in the gut and brain. Starting at a low dose gives those pathways time to adjust, cutting the rate of nausea and vomiting that tends to spike when higher doses are introduced too quickly. Think of it less as a dose that lacks effect and more as the body's four-week introduction to the medicine.

Clinical trial data for semaglutide at full maintenance doses, published in the STEP 1 trial in the New England Journal of Medicine, reported an average 15% body-weight reduction over 68 weeks at 2.4mg. That figure belongs to the full titrated course, not to any single dose in isolation. Skipping the starter phase doesn't fast-track results; it increases the chance of side effects that cause people to stop treatment before it has a real chance to work.

If you want to understand how the full dose sequence fits together, the Wegovy doses guide maps each step clearly.

How 2.5mg semaglutide sits within the licensed titration schedule

Wegovy's titration ladder runs: 0.25mg (note: this is the Wegovy pen lowest sub-step), the UK-licensed schedule begins with a 0.25mg weekly injection for four weeks, followed by 0.5mg for four weeks, then 1.0mg, then 1.7mg, reaching the standard maintenance dose of 2.4mg. The 2.5mg figure specifically refers to the oral semaglutide (Wegovy tablet) titration, where the equivalent lowest rung is 1.5mg. If you've seen "2.5mg semaglutide" in relation to injections, it may refer to a different product context, your prescriber will clarify which formulation and schedule applies to you.

For the Wegovy injection, each four-week step is a deliberate pause point. A prescriber reviews how you're tolerating the current dose before moving up. That clinical check is not a formality; people with persistent nausea at 0.5mg, for example, may stay at that level for longer before progressing. The semaglutide dosing overview explains how those decisions are made in practice.

The NHS's own patient information for semaglutide, available via nhs.uk/medicines/semaglutide, notes that the dose is always set by the prescriber and should never be adjusted by the patient alone. That applies equally at the start of treatment and at every subsequent step.

Side effects to expect at the starter dose, and when to seek help

Most people experience their strongest GI effects early in treatment or after a dose increase. At the starter level, common side effects include nausea, loose stools or constipation, mild indigestion and, less often, headache or fatigue. For many, these settle within the first week or two as the body adapts.

A few things worth knowing. Eating smaller portions, avoiding high-fat meals and staying well hydrated all help at this stage. Alcohol tends to worsen nausea. None of this replaces advice from your own prescriber, who is the right person to call if side effects feel difficult to manage.

There are symptoms that need prompt medical attention regardless of how early you are in treatment: severe, persistent stomach pain that spreads toward the back (a possible sign of pancreatitis), signs of a serious allergic reaction, or symptoms of dehydration after prolonged vomiting or diarrhoea. The MHRA's Yellow Card scheme allows patients to report suspected side effects directly to the regulator.

The 0.5mg semaglutide page covers what typically changes when the first dose increase arrives, including how side effects often behave at that transition.

Getting started: the private prescription route

Wegovy is prescription-only. The only legal route is a clinical assessment by a registered prescriber who decides whether treatment is appropriate for you. That assessment covers your BMI, any weight-related health conditions, your current medicines and whether there are any reasons semaglutide would not be suitable.

Eligible adults typically have a BMI of 30 or above, or 27 or above alongside a relevant health condition such as high blood pressure, type 2 diabetes or high cholesterol, though the prescriber's judgment covers more than the number alone. If you want to understand eligibility in more detail before committing to a consultation, the weight-loss treatment overview sets out who these medicines are licensed for.

Through nume, consultations are reviewed the same day by a GPhC-registered Independent Prescriber. If treatment is approved, dispatch follows that day for orders placed before 12pm on a working day, with tracked next-working-day DPD delivery. Our guidance on semaglutide daily dose considerations can help you understand what to expect once treatment begins. Pricing (one transparent figure that includes consultation, prescription and delivery, with no subscription) is on the treatment page. Start your free consultation there when you're ready to take the next step.